Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.

  title={Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.},
  author={Ludovic Martinet and R{\'e}my Poupot and Jean-Jacques Fourni{\'e}},
  journal={Immunology letters},
  volume={124 1},
Human TCRVgamma9Vdelta2+ gammadelta cells are unconventional T lymphocytes which had not been specifically mobilized in any cancer vaccine or immunotherapy so far, although they present the major advantage of mediating an HLA-unrestricted highly cytotoxic activity directed against most human tumor cell types. The rapid development of highly selective small molecule agonists targeting these lymphocytes has recently paved the way to clinical trials assessing their activity against cancer. Despite… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
19 Extracted Citations
138 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 19 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 138 references

A regulatory cross-talk between V 9V 2 T lymphocytes and mesenchymal stem cells

  • L Martinet, S Fleury-Cappelleso, M Gadelorge, G Dietrich, P Bourin, JJ Fournie
  • Eur J Immunol 2009;(February 5) [Epub ahead of…
  • 2009
Highly Influential
3 Excerpts

Mesenchymal stem cell - like cells derived from human gastric cancer tissues

  • RM Dwyer, SM Potter-Beirne, KA Harrington, AJ Lowery, E Hennessy
  • Cancer letters
  • 2009

Phosphoantigens and aminobisphosphonates: new leads targeting T lymphocytes for cancer immunotherapy

  • C Belmant, D Decise, JJ. Fournie
  • Drug Discov Today: Therapeut Strategies 2006;3:17…
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…